# Overlapping forms of granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis: Insights from a European multicenter study

**Authors:** Federica Pallotti, Camille Mettler, Matthias Papo, Michele Iudici, Roberto Padoan, Boris Sorin, Francesca Regola, Franco Franceschini, Sergey Moiseev, Pavel Novikov, Mario Andrea Piga, Gianluca Moroncini, Silke R. Brix, Abdul Hadi Kafagi, Samuel Deshayes, Achille Aouba, Julien Campagne, Paolo Delvino, Jan Willem Cohen Tervaert, Luisa Brussino, Martin Michaud, Nils Venhoff, Federico Alberici, Claudia Iannone, Sophie Rosenstingl, Marin Moutel, Jean‐Marc Galempoix, Vincent Cottin, Clara Jaccard, Diane Riehl, Paul Legendre, Anne Claire Billet, Paola Parronchi, Luca Quartuccio, Vitor Teixeira, Allyson Egan, David Jayne, Enrico Tombetti, Marco Caminati, Christian Pagnoux, Alexis Regent, Marc Ruivard, Loïc Guillevin, Xavier Puéchal, Benjamin Terrier

PMC · DOI: 10.1111/joim.70056 · Journal of Internal Medicine · 2025-12-09

## TL;DR

This study explores overlapping features between two types of vasculitis, EGPA and GPA, revealing distinct patient clusters with different clinical outcomes and treatment needs.

## Contribution

The study identifies distinct subtypes of overlapping EGPA/GPA and highlights their clinical and therapeutic implications.

## Key findings

- Three distinct patient clusters were identified with varying clinical features and survival outcomes.
- Cluster 1 showed a hybrid EGPA/GPA phenotype with high relapse rates and better survival.
- Cluster 3 had severe vasculitis and the poorest survival, aligning more with GPA.

## Abstract

Granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA) are distinct forms of antineutrophil cytoplasm antibody (ANCA)‐associated vasculitis (AAV). Increasing evidence suggests overlapping features, particularly in proteinase 3 (PR3)‐ANCA‐positive EGPA and GPA with eosinophilia. This study aimed to characterize overlapping EGPA/GPA forms and assess their clinical and therapeutic implications.

We conducted a European, multicenter, observational study, including 135 patients with overlapping EGPA/GPA features. Definitions were based on ACR/EULAR classification criteria and other clinical and biological findings. Clinical, biological, and histological characteristics were analyzed using unsupervised hierarchical clustering approach. Comparisons were made with established EGPA and GPA control cohorts.

Three clusters emerged: Cluster 1, a hybrid phenotype (pulmonary nodules, PR3‐ANCA positivity, high relapse rate); Cluster 2, a systemic inflammatory phenotype (constitutional symptoms, PR3‐ANCA positivity, moderate renal involvement); and Cluster 3, a severe vasculitis form (severe renal disease, alveolar hemorrhage). Including typical EGPA and GPA control cohorts revealed two main clusters a posteriori: an EGPA cluster and a GPA cluster. Cluster 1 overlapped with both EGPA and GPA clusters, whereas Clusters 2 and 3 predominantly aligned with GPA. Kaplan–Meier analysis revealed that Cluster 1 and the typical EGPA cohort had the best overall survival, whereas Cluster 3 had the poorest survival. Relapse‐free survival was highest in typical EGPA and poorest in Cluster 3 and typical GPA.

This study delineates the heterogeneity of EGPA/GPA overlap and underscores the need for personalized treatment approaches. Future prospective studies should explore targeted therapies, including rituximab and IL‐5 blockade, in these overlapping AAV subtypes.

## Linked entities

- **Chemicals:** IL-5 (PubChem CID 57407714)
- **Diseases:** Granulomatosis with polyangiitis (MONDO:0012105), eosinophilic granulomatosis with polyangiitis (MONDO:0015943), AAV (MONDO:0015492)

## Full-text entities

- **Genes:** IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, PRTN3 (proteinase 3) [NCBI Gene 5657] {aka ACPA, AGP7, C-ANCA, CANCA, MBN, MBT}
- **Diseases:** inflammatory (MESH:D007249), EGPA (MESH:D014890), eosinophilia (MESH:D004802), renal involvement (MESH:C565423), AAV (MESH:D014657), renal disease (MESH:D007674), antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (MESH:D056648), alveolar hemorrhage (MESH:D006470)
- **Chemicals:** rituximab (MESH:D000069283)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12869015/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12869015/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12869015/full.md

---
Source: https://tomesphere.com/paper/PMC12869015